Ipilimumab for Head and Neck Cancer Patients

Part of paid clinical trials in Portland, Oregon.

Sponsor
Providence Health & Services
Study ID
NCT02812524
Phase
PHASE1
Status
Active Not Recruiting

Conditions

  • Squamous Cell Carcinoma of the Head and Neck

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Intratumoral Ipilimumab — DRUG
    Patients with a planned resection of SCCHN will have a biopsy procedure 7-10 days prior to surgery and receive an injection of ipilimumab directly into a tumor.

Study Details

This study is for patients with squamous cell carcinoma of the head and neck (SCCHN). This study will test the feasibility of the administration of intratumoral injections of ipilimumab prior to surgical resection, and the immune system response to treatment.

Key Dates

Start date
Nov 18, 2016
Status verified
Apr 2026
Primary completion
Sep 21, 2019
Completion
Dec 31, 2026

Study Design

Enrollment
18 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Intratumoral Ipilimumab
    Patients receive a 3mg intratumoral injection of ipilimumab during a biopsy procedure.

Primary Outcome Measure

Surgery delay [ Time Frame: 7-10 Days ]

Locations (1)

FacilityCityStateZIPSite coordinators
Portland Providence Medical CenterPortlandOregon97213-

Find similar trials in Portland, OR

By research site
Portland Providence Medical Center· Portland, OR

Related Studies